New Series of COX-2-Selective Inhibitors
J ournal of Medicinal Chemistry, 2001, Vol. 44, No. 3 361
Kennedy, B.; Leblanc, Y.; Le´ger, S.; Mancini, J .; O′Neill, G. P.;
Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger,
Y.; Tagari, P.; The´rien, M.; Vickers, P.; Wong, E.; Xu, L.-J .;
Young, R. N.; Zamboni, R. The Discovery of Rofecoxib [MK 966,
Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an
Orally Active Cyclooxygenase-2 Inhibitor. Bioorg. Med. Chem.
Lett. 1999, 9, 1773-1778.
for their excellent technical assistance and J ordi Belloc
for the GC, MS, and HPLC analyses.
Su p p or tin g In for m a tion Ava ila ble: Combustion analy-
ses and 1H NMR spectra for all compounds. This material is
(16) J ackson, L. M.; Hawkey, C. J . Gastrointestinal effects of COX-2
Inhibitors. Exp. Opin. Invest. Drugs 1999, 8, 963-971.
(17) Beswick, P. J .; Campbell, Y. B.; Naylor, A. (Glaxo) Patent
WO9631509, 1996.
(18) Gungor, T.; Teulon, J. M. (Laboratoires Upsa) Patent WO9805639,
1998.
Refer en ces
(1) (a) Vane, J . R. Inhibition of Prostaglandin Synthesis as
a
Mechanism of Action of Aspirin-like Drugs. Nature 1971, 231,
232-235. (b) Vane, J . R.; Ferreira, S. H. Antiinflammatory
Drugs; Springer-Verlag: Berlin, 1979; pp 305-347.
(19) Biftu, T.; Heck, J . V.; Thorsett, E. D. (Merck and Co.) Patent
EP308020, 1988.
(2) (a) Sontag, S. J . Prostaglandins in Peptic Ulcer Disease. An
Overview of Current Status and Future Directions. Drugs 1986,
32, 445-457. (b) Allison, M. C.; Howatson, A. G.; Torrance, C.
J .; Lee, F. D.; Russell, R. Y. G. Gastrointestinal Damage
Associated with the Use of Nonsteroidal Antiinflammatory
Drugs. N. Engl. J . Med. 1992, 327, 749-754.
(20) (a) Bajwa, J . S.; Sykes, P. J . Synthesis and Structure of Some
Azolo[a]pyrimidines. J . Chem. Soc., Perkin Trans. 1979, 3085-
3094. (b) Van Haverbeke, Y.; Maquestiau, A.; Vanden Eynde, J .
J . J . Heterocycl. Chem. 1979, 16, 773. (c) Makisumi, Y. Studies
on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubsti-
tuted Pyrazolo[1,5-a]pyrimidines. Chem. Pharm. Bull. 1962, 10,
620-626. (d) Auzzi, G.; Cecchi, L.; Costanzo, A.; Pecori Vettori,
L.; Bruni, F.; Pirisino, R.; Ciottoli, G. B. Farmaco Ed. Sci. 1978,
34, 478-485.
(21) Clive, D. L. J .; Bergstra, R. J . Short Synthesis of (+)-5-(3-Furyl)-
octahydro-8-methylindolizines, Alkaloids Related to a Compo-
nent of Castoreum. Use of Radical Cyclization. J . Org. Chem.
1991, 56, 4976-4977.
(22) Li, W.-S.; Liu, L. K. A Convenient Oxidation of Benzylic Methyl,
Methylene, and Methine Groups with Potassium Permanganate/
Triethylamine Reagent. Synthesis 1989, 293-295.
(23) DeVleeschauwer, M.; Gauthier, J . Y. Remarkably Mild and
Simple Preparation of Sulfinates, Sulfonyl Chlorides and Sul-
fonamides form Thioanisoles. Synlett 1997, 375-376.
(24) Novinson, T.; Okabe, T.; Robins, R. K.; Metthews, T. R. Synthesis
and Antimicrobial Activity of Some Novel Heterocycles. Azolo-
as-triazines. J . Med. Chem. 1976, 19, 517-520.
(25) Senga, K.; O’Brien, D.; Scholten, M. B.; Novinson, T.; Miller, J .
P.; Robins, R. K.; Synthesis and Enzymic Activity of Various
Substituted Pyrazolo[1,5-a]-1,3,5-triazines as Adenosine Cyclic
3′5′-Phosphate Phosphodiesterase Inhibitors. J . Med. Chem.
1982, 25, 243-249.
(26) Spitzer, W. A.; Victor, F.; Pollock, G. D.; Hayes, J . S. Imidazo-
[1,2-a]pyrimidines and Imidazo[1,2-a]pyrazines: The Role of
Nitrogen Position in Inotropic Activity. J . Med. Chem. 1988, 31,
1590-1595.
(27) Glaser, K.; Sung, M. L.; O′Neill, K.; Belfast, M.; Hartman, D.;
Carlson, R.; Kreft, A.; Kubrak, D.; Hsiao, C. L.; Weichman, B.
Etodolac Selectively Inhibits Human Prostaglandin G/H Syn-
thase 2 (PGHS-2) versus Human PGHS-1. Eur. J . Pharmacol.
1995, 281, 107-111.
(28) Winter, C. A.; Risley, E. A.; Nuss, G. W. Carrageenin -Induced
Edema in Hind Paw of the Rat as an Assay for Antiinflammatory
Drugs. Proc. Soc. Exp. Biol. Med. 1962, 111, 544-547.
(29) Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J .;
Perkins, W.; Lee, L.; Isakson, P. Pharmacological and Biochemi-
cal Demonstration of the Role of Cyclooxygenase 2 in Inflam-
mation and Pain. Natl. Acad. Sci. U.S.A. 1994, 91, 12013-12017.
(30) Chan, C.; Boyce, S.; Brideau, C.; Ford-Hutchinson, A. W.;
Gordon, R.; Guay, D.; Hill, R. G.; Li, C.; Mancini, J .; Penneton,
M.; Prasit, P.; Rasori, R.; Riendeau, D.; Roy, P.; Tagari, P.;
Vickers, P.; Wong, E.; Rodger, Y. W. Pharmacology of a Selective
Cyclooxygenase-2 Inhibitor, L-745,337: A Novel Nonsteroidal
Antiinflammatory Agent with an Ulcerogenic Sparing Effect in
Rat and Nonhuman Primate Stomach. J . Pharmacol. Exp. Ther.
1995, 274, 1531-1537.
(31) Ainswoth, C. Indazole. Org. Synth. Coll. Vol. IV 1963, 536-539.
(32) Reich, M. F.; Fabio, P. F.; Lee, V. J .; Kuck, N. A.; Testa, R. T.
Pyrido[3,4-e]-1,2,4-triazines and Related Heterocycles as Poten-
tial Antifungal Agents. J . Med. Chem. 1989, 32, 2474-8.
(33) Horning, R. H.; Amstutz, E. D. The preparation of some dialkyl
pyridazines. J . Org. Chem. 1955, 20, 707-713.
(3) Clive, D. M.; Stoff, J . S. Renal Syndromes Associated with
Nonsteroidal Antiinflammatory Drugs. N. Engl. J . Med. 1984,
310, 563-572.
(4) (a) Xie, W.; Chipman, J . G.; Robertson, D. L.; Erikson, R. L.;
Simmons, D. L. Expression of
a Mitogen-responsive Gene
Encoding Prostaglandin Synthase is Regulated by mRNA Splic-
ing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696. (b)
J ujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.;
Herschman, H. R. TIS10, a Phorbol Ester Tumor Promoter-
Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Pros-
taglandin Synthase/Cyclooxygenase Homologue. J . Biol. Chem.
1991, 266, 12866-12872.
(5) (a) Vane, J . R. Towards a Better Aspirin. Nature 1994, 367, 215-
216. (b) Masferrer, J . L.; Zweifel, B. S.; Manning, P. T. Selective
Inhibition of Inducible Cyclooxygenase-2 in vivo is Antiinflam-
matory and Nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994,
91, 3228-3232.
(6) Kalgutkar, A. S. Selective Cyclooxygenase-2 Inhibitors as Non-
ulcerogenic Antiinflammatory Agents. Exp. Opin. Ther. Patents
1999, 9, 831-849.
(7) Kurumbail, R. G.; Stevens, A. M.; Gierse, J . K.; McDonald, J .
J .; Stegeman, R. A.; Pak, J . Y.; Gildehaus, D.; Miyashiro, J . M.;
Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C.
Structural Basis for Selective Inhibition of Cyclooxygenase-2 by
Antiinflammatory Agents. Nature 1996, 384, 644-648.
(8) Leblanc, Y.; Black, W. C.; Chan, C. C.; Charleson, S.; Delorme,
D.; Denis, D.; Gauthier, J . Y.; Grimm, E. L.; Gardon, R.; Guay,
D.; Hamel, P.; Kargman, S.; Lau, C. K.; Mancini, J .; Ouellet,
M.; Percival, D.; Roy, P.; Skorey, K.; Tagari, P.; Vickers, P.;
Wong, E.; Xu, L.; Prasit, P. Biorg. Med. Chem. Lett. 1996, 6,
731-736.
(9) Woods, K. M.; McCroskey, R. W.; Michaelides, M. R. (Abbott)
Patent WO9839330, 1997.
(10) Klein, T.; Nusing, R. M.; Pfeilschifter, J .; Ullrich, V. Selective
Inhibition of Cyclooxygenase 2. Biochem. Pharmacol. 1994, 48,
1605-1610.
(11) Li, C. S.; Black, W. C.; Chan, C.; Ford-Hutchinson, A. W.;
Gauthier, J . Y.; Gordon, R.; Guay, D.; Kargman, S.; Lau, C. K.;
Mancini, J .; Ouimet, N.; Roy, P.; Vickers P.; Wong, E.; Young,
R. N.; Zamboni, R.; Prasit, P. Cyclooxygenase-2 Inhibitors.
Synthesis and Pharmacological Activities of 5-Methanesulfona-
mido-1-indanone Derivatives. J . Med. Chem. 1995, 38, 4897-
4905.
(12) Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, Y.; Higuchi, S.;
Iizuka, H.; Otomo, S. NS-398, a Novel Nonsteroidal Antiinflam-
matory Drug with Potent Analgesic and Antipyretic Affects,
which Causes Minimal Stomach Lesions. Gen. Pharmacol. 1993,
24, 105-10.
(13) (a) Reitz, D. B.; Isakson, P. C. Cyclooxygenase-2 Inhibitors. Curr.
Pharm. Des. 1995, 1, 211-220. (b) Carter, J . S. Recently
Reported Inhibitors of Cyclooxygenase-2. Exp. Opin. Ther.
Patents 1997, 8, 21-29.
(14) Penning, T. D.; Talley, J . J .; Bertenshaw, S. R.; Carter, J . S.;
Collins, P. W.; Docter, S.; Graneto, M. J .; Lee, L. F.; Malecha, J .
W.; Miyashiro, J . M.; Rogers, R. S.; Rogier, D. J .; Yu, S. S.;
Anderson, G. D.; Burton, E. G.; Cogburn, J . N.; Gregory, S. A.;
Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.;
Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation
of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:
Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-
pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J . Med.
Chem. 1997, 40, 1347-1365.
(34) Sato, N.; Matsuura, T.; Miwa, N. Studies on Pyrazines; Part
30: Synthesis of Aminopyrazines from Azidopyrazines. Synthesis
1994, 931-934.
(35) Nakamura, H.; Aizawa, M.; Murai, A. Direct Alkylation of
2-Acylamino- and 2-Aminopyrazines with Organolithium Re-
agents. Synlett 1996, 1015-1016.
(15) Prasit, P.; Wang, Z.; Brideau, C., Chan, C.-C., Charleson, S.;
Cromlish, W.; Ethier, D.; Evans, J . F.; Ford-Hutchinson, A. W.;
Gauthier, J . Y.; Gordon, R.; Guay, J .; Gresser, M.; Kargman, S.;
J M0009383